148 related articles for article (PubMed ID: 6224678)
1. In vitro antibacterial activity of norfloxacin compared with eight other antimicrobial agents.
Body BA; Fromtling RA; Shadomy S; Shadomy HJ
Eur J Clin Microbiol; 1983 Jun; 2(3):230-4. PubMed ID: 6224678
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.
Neu HC; Labthavikul P
Antimicrob Agents Chemother; 1982 Jul; 22(1):23-7. PubMed ID: 6214995
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of pefloxacin compared to that of quinolones and other antimicrobial agents.
Neu HC; Chin NX; Labthavikul P; Saha G
Chemioterapia; 1984 Aug; 3(4):235-41. PubMed ID: 6241847
[TBL] [Abstract][Full Text] [Related]
4. Antibacterial activity of norfloxacin.
Norrby SR; Jonsson M
Antimicrob Agents Chemother; 1983 Jan; 23(1):15-8. PubMed ID: 6219617
[TBL] [Abstract][Full Text] [Related]
5. Study of the in vitro activity of norfloxacin and other drugs on amoxicillin-resistant uropathogenic isolates.
Piccolomini R; Allocati N; Catamo G
Chemioterapia; 1984 Jun; 3(3):167-72. PubMed ID: 6241505
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of norfloxacin in urine compared to that of cinnoxacin, nalidixic acid and pipemidic acid.
Shah PM; Ottrad M; Stille W
Eur J Clin Microbiol; 1983 Jun; 2(3):272-4. PubMed ID: 6224688
[No Abstract] [Full Text] [Related]
7. In-vitro activity of norfloxacin against Enterobacteriaceae and Pseudomonas aeruginosa.
García-Rodríguez JA; Gómez-García AC; Rodrigo N
J Antimicrob Chemother; 1984 Aug; 14(2):192-3. PubMed ID: 6238928
[No Abstract] [Full Text] [Related]
8. Comparative in vitro activity of norfloxacin against urinary tract pathogens.
Haase D; Urias B; Harding G; Ronald A
Eur J Clin Microbiol; 1983 Jun; 2(3):235-41. PubMed ID: 6224679
[TBL] [Abstract][Full Text] [Related]
9. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920
[TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of pefloxacin compared to other antibiotics.
Yourassowsky E; Van der Linden MP; Crokaert F; Glupczynski Y
J Antimicrob Chemother; 1986 Apr; 17 Suppl B():19-28. PubMed ID: 3086279
[TBL] [Abstract][Full Text] [Related]
11. [Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1984). III. Secular changes in susceptibility].
Kosakai N; Kumamoto Y; Sakai S; Hirose T; Shigeta S; Shiraiwa Y; Miura Y; Ogata M; Tazaki H; Iri H
Jpn J Antibiot; 1986 Nov; 39(11):3019-93. PubMed ID: 3102809
[TBL] [Abstract][Full Text] [Related]
12. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
Guimaraes MA; Noone P
J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
[TBL] [Abstract][Full Text] [Related]
13. In vitro antibacterial activity of ceftizoxime against gram-negative strains.
Debbia E; Soro O
Chemioterapia; 1985 Apr; 4(2):166-9. PubMed ID: 3891115
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.
Barry AL; Jones RN; Thornsberry C; Ayers LW; Gerlach EH; Sommers HM
Antimicrob Agents Chemother; 1984 May; 25(5):633-7. PubMed ID: 6233935
[TBL] [Abstract][Full Text] [Related]
15. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H
Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757
[TBL] [Abstract][Full Text] [Related]
16. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2003 Oct; 56(5):458-96. PubMed ID: 14692381
[TBL] [Abstract][Full Text] [Related]
17. Disk diffusion susceptibility tests with norfloxacin: confirmation of proposed interpretive criteria.
Wood SJ; Shadomy S
Eur J Clin Microbiol; 1983 Jun; 2(3):242-4. PubMed ID: 6224680
[TBL] [Abstract][Full Text] [Related]
18. In vitro antibacterial activity of norfloxacin and other agents against ocular pathogens.
Shungu DL; Tutlane VK; Weinberg E; Gadebusch HH
Chemotherapy; 1985; 31(2):112-8. PubMed ID: 3157551
[TBL] [Abstract][Full Text] [Related]
19. [Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1984). I. Susceptibility distribution].
Kosakai N; Kumamoto Y; Sakai S; Hirose T; Shigeta S; Shiraiwa Y; Miura Y; Ogata M; Tazaki H; Iri H
Jpn J Antibiot; 1986 Nov; 39(11):2959-3006. PubMed ID: 3102808
[TBL] [Abstract][Full Text] [Related]
20. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
Jpn J Antibiot; 1995 Nov; 48(11):1627-57. PubMed ID: 8558754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
